Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swiss study aims to find hidden cancer genes in families

NCT ID NCT03124212

Knowledge-focused Sponsor: University of Basel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at families in Switzerland who carry genes that raise the risk of breast, ovarian, colorectal, or endometrial cancers. Researchers will survey both the person with the gene mutation and their close relatives to understand how many get tested and what barriers they face. The goal is to find better ways to offer genetic counseling and testing to prevent cancer deaths.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2017

Expected to finish

Jan 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Living carriers of pathogenic mutations associated with HBOC and LS, and their blood relatives (first- and second-degree, and first cousins)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Carrier of a mutation associated with HBOC or LS 2. Have at least one living blood relative 3. Men and women 4. 18 years old and older 5. Mentally and physically able to provide informed consent 6. Can read and speak German or French or Italian or English 7. Currently living in Switzerland. Exclusion Criteria: 1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes 2. Not living in Switzerland 3. Patients who are critically ill and cannot complete the CASCADE survey 4. Participants who are institutionalized (e.g., nursing homes) or incarcerated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary breast and ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis hereditary breast ovarian cancer syndrome Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary breast and ovarian cancer Lynch syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gastroenterology clinic

    TERMINATED

    Bern, 2010, Switzerland

  • HFR Fribourg - Hôpital Cantonal

    NOT_YET_RECRUITING

    Fribourg, Canton of Fribourg, 1752, Switzerland

  • Hirslanden Clinic Des Grangettes

    NOT_YET_RECRUITING

    Geneva, Canton of Geneva, 1224, Switzerland

  • Hôpital du Jura Service d'Oncologie

    RECRUITING

    Delémont, Canton of Jura, 2800, Switzerland

  • Istituto Oncologico della Zvizzera Italiana

    RECRUITING

    Bellinzona, 6962, Switzerland

  • Katonsspital Winterthur Tumorzentrum Brustzentrum

    NOT_YET_RECRUITING

    Winterthur, Canton of Zurich, 8401, Switzerland

  • Unite d'Oncogenetique et de Prevention des Cancers

    RECRUITING

    Geneva, 1205, Switzerland

  • Universitatklinik fur Medizinische Onkologie, Inselspital

    RECRUITING

    Bern, 3010, Switzerland

  • University Hospital Basel

    RECRUITING

    Basel, 4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.